Special Issue

Advances in Antibody-Drug Conjugates (ADCs)

Message from the Guest Editor

Antibody-drug conjugates (ADCs) are a class of pharmaceutical products designed to target cancer cells for treating a wide variety of cancers. Most of the ADCs developed or in clinical trials are for oncology and hematology indications, but there are attempts to expand the indications to other disease areas. ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic drug forming a conjugate. The cytotoxic drug has the ability to kill cancer cells and is designed to distinguish between healthy and cancerous cells. In order to develop a therapeutically beneficial ADC, it is important to understand its chemistry, mechanism of action, pre-clinical pharmacology, clinical pharmacology, and safety and efficacy. Therefore. We are inviting experts from the aforementioned disciplines to contribute manuscripts on the different aspects of the development of ADCs.

Guest Editor

Dr. Iftekhar Mahmood

Mahmood Clinical Pharmacology, Consultancy, LLC, 1709, Piccard Dr, Rockville, MD 20850, USA

Deadline for manuscript submissions

closed (10 October 2021)



an Open Access Journal by MDPI

Impact Factor 2.7
CiteScore 4.5
Indexed in PubMed



mdpi.com/si/58662

Antibodies
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibodies@mdpi.com

mdpi.com/journal/ antibodies





an Open Access Journal by MDPI

Impact Factor 2.7 CiteScore 4.5 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Editor-in-Chief

Prof. Dr. Arne Skerra

Institute of Biological Chemistry, Technical University Munich, Emil-Erlenmeyer-Forum 5, 85350 Freising-Weihenstephan, Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Drug Discovery)

